Publications by authors named "Daniel Jacoby"

Claim this Profile
T
Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling.
Donghong Xu, Hanbin Li, Stephen B Heitner, Daniel L Jacoby, Stuart Kupfer

CPT Pharmacometrics Syst Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.
Sheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, Stoyan Getchevski, Ahmad Masri, Daniel L Jacoby

J Am Coll Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM.
Juan Pablo Kaski, Paul F Kantor, Stephanie J Nakano, Iacopo Olivotto, Mark W Russell, Daniel L Jacoby

Circ Heart Fail· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM.
Xiaowen Wang, Maria A Pabon, Tracy T Makuvire, Reziwanguli Maimaiti, Theodore P Abraham, Daniel L Jacoby

Circ Heart Fail· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
Andrew Wang, Pablo Garcia-Pavia, Ahmad Masri, Bela Merkely, Michael E Nassif, Daniel L Jacoby

J Am Coll Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
Joseph Campain, Catharine Griskowitz, Chloe Newlands, Brian L Claggett, Ian J Kulac, Daniel L Jacoby

Circulation· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.
Martin S Maron, Juan Ramon Gimeno, Josef Veselka, Roberto Barriales-Villa, Brian L Claggett, Daniel L Jacoby

Eur Heart J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation.
John C Stendahl, Sounok Sen, Michael Butzner, Eros Papademetriou, Ravi Potluri, Daniel Jacoby

J Am Heart Assoc· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Pablo Garcia-Pavia, Martin S Maron, Ahmad Masri, Bela Merkely, Michael E Nassif, Daniel L Jacoby

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.
Ahmad Masri, Mark V Sherrid, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M Kramer, Daniel L Jacoby

J Card Fail· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up.
Ahmad Masri, Mandar Aras, Martha Grogan, Daniel Jacoby, Mathew S Maurer

J Card Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Sara Saberi, Theodore P Abraham, Lubna Choudhury, Roberto Barriales-Villa, Perry M Elliott, Daniel L Jacoby

JACC Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials.
Ethan J Rowin, Martin S Maron, Iacopo Olivotto, Caroline J Coats, Theodore P Abraham, Daniel L Jacoby

Heart Rhythm· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy and Mild Symptoms: Results from the SEQUIOA-HCM Trial.
Martin S Maron, Juan Ramon Gimeno, Josef Veselka, Roberto Barriales-Villa, Brian L Claggett, Daniel L Jacoby

Eur Heart J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Ahmad Masri, Martin S Maron, Theodore P Abraham, Michael E Nassif, Roberto Barriales-Villa, Daniel L Jacoby

JACC Heart Fail· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics.
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, Juan Pablo Costabel, Edileide de Barros Correia, Daniel L Jacoby

JACC Heart Fail· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.
Caroline J Coats, Ahmad Masri, Roberto Barriales-Villa, Theodore P Abraham, Douglas Marshall Brinkley, Daniel L Jacoby

Eur Heart J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Sheila M Hegde, Brian L Claggett, Xiaowen Wang, Karola Jering, Narayana Prasad, Daniel L Jacoby

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy.
Ahmad Masri, Rhanderson N Cardoso, Theodore P Abraham, Brian L Claggett, Caroline J Coats, Daniel L Jacoby

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Charles F Sherrod, Sara Saberi, Michael E Nassif, Brian L Claggett, Caroline J Coats, Daniel L Jacoby

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.
Matthew M Y Lee, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Theodore P Abraham, Daniel L Jacoby

JAMA Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Martin S Maron, Ahmad Masri, Michael E Nassif, Roberto Barriales-Villa, Theodore P Abraham, Daniel L Jacoby

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM.
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, Perry Elliott, Martin S Maron, Daniel L Jacoby

J Am Coll Cardiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathy.
Supriya Shore, Claire Ervin, Katherine Kosa, Sheri Fehnel, Lisa Salberg, Daniel Jacoby

BMJ Open· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten for Obstructive Hypertrophic Cardiomyopathy. Reply.
Martin S Maron, Caroline J Coats, Daniel L Jacoby

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis